Patients with metastasized soft tissue sarcoma: Quality of life under chemotherapy or pazopanib treatment

GISG 11, PazoQoL

Coordinating investigator

Dr. med.
Luzerner Kantonsspital
+41 41 205 58 37

For patients with advanced or metastasized soft tissue sarcoma, personal needs and quality of life are the main priorities when treatment decisions have to be made, especially in palliative situations. Such decisions must take account of side effects such as fatigue, nausea and loss of appetite that can greatly impair the patient's quality of life.

The PazoQoL study investigates the quality of life of patients with advanced or metastasized soft tissue sarcoma under two different treatment regimes. Since it is known that doctors often assess the gravity and relevance of side effects differently from patients, in this study the participants assess their quality of life themselves.

The 150 trial subjects are randomly assigned to two groups. The patients in one group receive a standard chemotherapy according to the recommendations of their treating physician. The patients in the other group take a daily dose of pazopanib (Votrient®) – a medicine that is approved in Switzerland for the treatment of advanced soft tissue sarcoma. In the first nine weeks, each patient assesses his or her quality of life eight times using a standardized questionnaire. The subsequent follow-up phase lasts a maximum of two years: Every twelve weeks, the patients go to their physician for a check-up and fill out another questionnaire on their quality of life.


All trials